Alcon has announced a strategic collaboration with RxSight to develop adjustable presbyopia-correcting intraocular lenses (IOLs), marking a significant milestone in the future of premium cataract surgery.
By combining Alcon's expertise in presbyopia-correcting IOL optical design with RxSight's innovative Light Adjustable Lens (LAL) technology, the collaboration aims to bring a new level of precision and personalisation to cataract surgery. Unlike conventional premium intraocular lenses, this technology has the potential to allow surgeons to adjust a patient's prescription after cataract surgery using non-invasive UV light treatments, helping to optimise visual outcomes once the eye has healed.
While multifocal and extended depth of focus (EDOF) intraocular lenses have transformed vision correction for many cataract patients, achieving the ideal refractive outcome can still be challenging. Even minor residual refractive errors can affect visual quality and patient satisfaction. The Alcon and RxSight collaboration is designed to address this challenge by enabling surgeons to:
If successfully commercialised, adjustable presbyopia-correcting IOLs could represent a significant advancement in premium cataract surgery by combining advanced optical design with personalised postoperative vision correction.
The partnership brings together two leaders in ophthalmic innovation. Alcon is recognised globally for its expertise in surgical ophthalmology and premium presbyopia-correcting intraocular lenses, while RxSight has pioneered the Light Adjustable Lens (LAL) platform, enabling surgeons to customise refractive outcomes after lens implantation. Together, the companies are working towards expanding the capabilities of adjustable lens technology beyond monofocal lenses and into the rapidly growing premium IOL market.
As patient expectations continue to evolve, precision and personalisation are becoming increasingly important in cataract surgery. Technologies that enable surgeons to optimise vision after surgery have the potential to improve clinical outcomes while increasing confidence in premium lens adoption. The collaboration between Alcon and RxSight reflects a broader trend across ophthalmology: combining innovative optics with advanced digital technologies to deliver more personalised patient care. Should the technology reach commercialisation, adjustable presbyopia-correcting intraocular lenses could help redefine the future of cataract surgery, offering greater flexibility, improved visual outcomes and a more tailored patient experience. As the ophthalmology industry continues to innovate, partnerships like this demonstrate how collaboration is accelerating the development of next-generation solutions that place personalised vision correction at the centre of patient care.